Abstract
Cyclosporin A, an potent immunosuppressant, has been known to be one of the modulators of drug resistance as well as a cytostatic drug. Despite many attempts to basic or clinical application of cyclosporin A, there are few reports on the inhibition of brain tumor cells. In the present experiment, the possibility of cyclosporin A as synergic adjuvant was investigated by MTT assay, [3H] thymidine uptake and through flowcytometric analysis. Sole treatment of cyclosporin A on the CRT and CH235-MG glioma cell line revealed dose dependent cytotoxicity within a range of tested dose. Combined treatment of cyclosporin A with ACNU, BCNU and hydroxyurea on various glioma cancer cell line led to a significant synergistic cytotoxicity as well as inhibition of DNA synthesis with dose-dependency. In addition, cyclosporin A alone or combined treatment caused discernible changes of cell cycle in the tested cells. These data provide that cyclosporin A could potentiate the effect of nitrosourea compoundsin vitro on human glioma cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Berguli, L., Gregoretti, M. G. and Caligaris-Cappio, F., Cyclosporin A in the treatment of B-chronic lymphocytic leukemia (B-CLL).Leukemia, 8, 1245–1246 (1994).
Blasberg, R. G. and Groothuis, D. R., Chemotherapy of brain tumors: physiological and pharmacokinetic considerations.Semin. Oncol., 13, 70–82 (1986).
Botling, J., Liminga, G., Larsson, R., Nygren. P. and Nilsson, K., Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.Int. J. Cancer., 58, 269–274 (1994).
Carmichael, J., deGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchel, J. B., Evaluation of a tetrazolium-based semiautomated colorimetric assay; assessment of radiosensitivity.Cancer. Res., 47, 936–942 (1987).
Chang, C. H., Horton, J., Schoenfeld, D. and Salazer, O., Comparison of postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas.Cancer, 52, 997–1007 (1983).
Cho, K. G., Nagashima, T., Barnwell, S. and Hoshino, T., Flowcytometric determination of modal DNA population in relation to proliferative potential of human intracranial neoplasms.J. Neurosurg., 69, 588–592 (1988).
Gitter, B. D., Waters, D. C., Threlkeld, P. G., Lovelace, A. M., Matsumoto, K. and Bruns, R. F., Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.Eur. J. Pharmacol., 26, 289, 439-446 (1995).
Golden, G. S., Ghatak, N. R., Hirano, A. and French, J. H., Malignant glioma of the brain stem: a clinicopathological analysis of 13 cases.J. Neurol. Neurosurg. Psychiarty., 35, 732–738 (1972).
Gordon, H. B., William, T. C., Jean-Guy V. and Voon, W. Y., Protein kinase C inhibitor suppress cell growth in established and low-passage glioma cell lines. A comparison between stausporine and tamoxifen.Neurosurgery, 33, 495–501 (1993).
Kaye, A. H. and Laidlaw, J. D., Chemotherapy of gliomas.Curr. Opin. Lipidol., 5, 526–533 (1992).
Kim, S. K., Ahn, C. M., Kim, T. U., Choi, S. J., Park, Y. S., Shin, W. S. and Koh, C. M.,In vitro chemosensitivity test of SK-302B on human colon carcinoma cell lines.Arch. Pharm. Res., 19, 261–263 (1996).
Kronke, M., Leonard, W. J. and Depper, J. M., Cyclosporin A inhibits T cell growth factor gene expression at the level of m RNA transcription.Proc. Natl. Acad. Sci. USA., 81, 5124 (1984).
Linskey, M. E. and Gilbert, M. R., Glial differentiation: A review with implications for new directions in neuro-oncology.Neurosurgery, 36, 1, 1–21 (1995).
Ministry of Health and Social Affairs, Five years report for cancer register program in the republic of Korea (1982.7.1–1989.6.30).J. Kor. Cancer. Ass., 21, 155–217 (1989).
Paoletti, P., Butti, G., Knerich, R., Gaetani, P. and Assietti, R., Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.Acta Neurochir., 103, 38–46 (1990).
Piontek, M. and Porschen, R., Growth inhibition of human gastrointestinal cancer cells by cyclosporin A.J. Cancer Res. Clin. Oncol., 120, 695–699 (1994).
Rogers, L. R., Purvis., J. B., Lederman, R. J. and Roswenbloom, S. A., Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma.Cancer, 68, 15–21 (1991).
Sakata, A., Tamai, I., Kawazu, K., Deguchi, Y., Ohnish, T., Saheki, A. and Tsuji, A.,In vivo evidence for ATP-dependent and P-glycoprotein.-mediated transport of cyclosporin A at the blood-brain barrier.Biochem., Pharmcol., 48, 1989–1992 (1994).
Shapiro, W. R. and Shapiro, J. R., Principles of brain tumor chemotherapy.Semin. Oncol., 13, 56–59 (1986).
Soma, M. R., Pagliarini, P., Butti, G., Paoletti, R. and Poletti, P., Fumagalli, R., Simvastin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chlorethyl)-N-nitrosourea and interferon on human glioma cells.Cancer Res., 52, 4388–4355 (1992).
Thornton, D. E., Villasmil, P., Staubus, A. and Asif, M., A phase I study of cyclosporin A with Ara-C, mitoxantrone, etoposide in relapsed AML.Proc. Am. Assoc. Cancer Res., 35, A1343 (1994).
Waker, M. D., Green, S. B., Byar, D. P. and Batzdorf, U., Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.N. Engl. J. Med., 303, 1323–1329 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pyen, J.S., Kim, S.K., Choi, SJ. et al. The effect of cyclosporin A on the growth of human glioma cell lines. Arch. Pharm. Res. 20, 379–383 (1997). https://doi.org/10.1007/BF02976205
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976205